Posted by Michael Wonder on 15 Mar 2021
Health economic assessment of Zolgensma in spinal muscular atrophy
12 March 2021 - TLV has produced a health economic assessment for the regions for Zolgensma (onasemnogene abeparvovec) in the treatment of spinal muscular atrophy of type 5q.
The comparison alternative to Zolgensma is Spinraza in combination with the best supportive care or best supportive care.
